Table 1.
Clinical and pathological characteristics of the study population
| Number | Percentage % | ||
|---|---|---|---|
| n = 202 | |||
| Age | |||
| <50 | 62 | 32.1 | |
| >50 | 131 | 67.8 | |
| Estrogen Receptor | |||
| Positive | 110 | 57.0 | |
| Negative | 83 | 43.0 | |
| Progesterone Receptor | |||
| Positive | 92 | 47.7 | |
| Negative | 101 | 52.3 | |
| HER2 Status | |||
| Positive | 27 | 14.0 | |
| Negative | 166 | 86.0 | |
| Subtype* | |||
| Luminal A | 84 | 43.5 | |
| Luminal B | 27 | 14.0 | |
| Her2 | 17 | 8.8 | |
| Triple Negative | 65 | 33.7 | |
| Pathologic Stage Group | |||
| 1 | 60 | 31.1 | |
| 2 | 80 | 41.5 | |
| 3 | 40 | 20.7 | |
| 4 | 12 | 6.2 | |
| Unknown | 1 | 0.5 | |
| Grade | |||
| I | 9 | 4.6 | |
| II | 54 | 28.0 | |
| III | 130 | 67.4 | |
| Recurrence | |||
| None | 147 | 76.2 | |
| Loco-regional | 8 | 4.1 | |
| Distant | 21 | 10.9 | |
| Never Disease free | 8 | 4.1 | |
| Unknown | 9 | 4.7 |
ER, estrogen receptor; PR, progesterone receptor.
*
Luminal A: ER+ or PR+, HER2−; luminal B: ER+ or PR+, HER2+ ; triple-negative: ER−, PR−, HER2−; Her2+: ER−, PR−, HER2+